Loading
WI
WW International, Inc. Stock: price and insider trades · United States
1 insider bought €86k of shares over the last 90 days, the latest filed 20 Aug 2026.
WW International, Inc.: what insiders have been doing
WW International, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). 6 insiders have disclosed 15 filings since 18 October 2025.
Not one open-market sale was filed. On the buying side, 4 insiders reported 7 purchases totalling €750k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The largest single trade was a purchase of €393k by Hawks Carney, published on 20 November 2025. Among those who bought: 3 senior executives and 1 finance chief.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 15 filings, this issuer sits below that mark. Since 2016, the database holds 17 purchases and 6 sales by insiders of the company.
The data flag 5 purchases as part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The most recent open-market purchase was published on 20 August 2026, 58 days ago. The median gap between a trade and its publication by SEC (Form 4) is 3 days. For comparison, the SEC allows two business days to file a Form 4.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
225
Thresholds
n/a
Buy Volume
€2M
17 ops. · all time
Sell Volume
€97M
6 ops. · all time
Who traded when
BuySaleEugene I. Davis4 buys
Carney Hawks1 buy
Felicia DellaFortuna1 buy
Nicole Haag1 sale
Nikolaj H. Sjoqvist1 buy
Since the insiders bought
- -17.0%Entry US$15.71 · Close 16 Oct 2026 US$13.04
- -23.7%Entry US$17.10 · Close 16 Oct 2026 US$13.04
- -23.7%Entry US$17.10 · Close 16 Oct 2026 US$13.04
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 9,884 of 24,148 companies
56.1
score / 100
Value53
Quality59
FCF yld-36%
Earn yld·
EV/EBITDA0.5x
ROE-31%
Gross mgn72%
Net mgn·
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$13.04
Analyst consensus
4 analysts2.33/5
US$20.00Target US$27.50(+111%)US$35.00
Income statement
RevenueUS$710.6M
Gross profitUS$510.5M72% margin
EBITDAUS$1.2B172% margin
Net incomeUS$1.1B-15.2% margin
Valuation
PER (trailing)0.1x
PER (forward)-558.9x
P/Book0.5x
Balance sheet & cash
Market capUS$130.4M
Total debtUS$468.6M
Free Cash Flow-US$46.4M
Debt / Equity153%
Profitability & ownership
ROE-30.7%
ROA-0.4%
% insiders8.2%
% institutions80.9%
Last declaration on 20 August 2026
Declarations225 total
7,235 shares@ US$13.840.069% mcap100.0% of flowCommon StockSEC:0001193125-26-359167:0
Canonical exit: 16 Nov 2026 (T+90)
1,029 shares@ US$14.35570.012% mcap5.0% of flowCommon StockSEC:0001193125-26-242074:2
Canonical exit: 25 Aug 2026 (T+90)
10,000 shares@ US$12.62510.10% mcap42.7% of flowCommon StockSEC:0001193125-26-242074:0
Canonical exit: 20 Aug 2026 (T+90)
1,648 shares@ US$13.48160.018% mcap7.5% of flowCommon StockSEC:0001193125-26-242074:1
Canonical exit: 24 Aug 2026 (T+90)
8,971 shares@ US$14.77620.11% mcap44.8% of flowCommon StockSEC:0001193125-26-242074:3
Canonical exit: 25 Aug 2026 (T+90)
1,500 shares@ US$12.6750.015% mcap100.0% of flowCommon StockSEC:0001193125-26-242079:0
Canonical exit: 20 Aug 2026 (T+90)
1,166 shares0Common StockSEC:0001193125-26-004371:0
1,166 shares0Common StockSEC:0001193125-26-004368:0
1,166 shares0Common StockSEC:0001193125-26-004367:0
1,166 shares0Common StockSEC:0001193125-26-004370:0
1,219 shares0Common StockSEC:0001193125-25-328681:0
1,219 shares0Common StockSEC:0001193125-25-328680:0
1,219 shares0Common StockSEC:0001193125-25-328674:0
1,219 shares0Common StockSEC:0001193125-25-328673:0
20,000 shares@ US$22.75100.0% of flowCommon StockSEC:0001193125-25-289719:0
Canonical exit: 17 Feb 2026 (T+90)
469 shares@ US$30.8633100.0% of flowCommon StockSEC:0000950170-25-110433:0
30,655 sharesCommon StockSEC:0000950170-25-090474:0
20,795 sharesCommon StockSEC:0000950170-25-090485:0
1,049 sharesCommon StockSEC:0000950170-25-090484:0
40,486 sharesCommon StockSEC:0000950170-25-090483:0
18,254 sharesCommon StockSEC:0000950170-25-090476:0
524,109 sharesCommon StockSEC:0000950170-25-090467:0
19,098 sharesCommon StockSEC:0000950170-25-090475:0
26,282 sharesCommon StockSEC:0000950170-25-090472:0
40,486 sharesCommon StockSEC:0000950170-25-090470:0
25 of 225 declarations
About WW International, Inc.
WW International, Inc. is a U.S.-listed company traded on the Nasdaq (ticker: WW), with headquarters in New York, United States. Best known historically as Weight Watchers, the company traces its roots back to 1963, when Jean Nidetch helped launch the original weight-management concept that later became one of the most recognizable consumer health brands in the world. Over time, WW has evolved from a meeting-based diet program into a broader weight-health platform that combines digital tools, coaching, community support, and, more recently, clinical care.
Today, the company’s business is best understood through two core pillars. The first is the “Behavioral” business, which includes digital subscriptions, coaching, workshops, and behavior-change tools designed to help members manage weight through structured lifestyle support. The second is the “Clinical” business, centered on WeightWatchers Clinic, formerly Sequence, which offers telehealth-based medical support, clinician-led care, and access to GLP-1 medications when medically appropriate. This shift reflects the broader transformation of the weight-management industry, where pharmacological solutions and integrated care pathways are increasingly shaping demand.
Read moreShow less
From a competitive standpoint, WW retains a strong legacy brand, deep consumer awareness, and decades of experience in commercial weight management. Its moat is not based on exclusivity, however, and the company competes with digital wellness apps, telehealth providers, nutrition platforms, and obesity-treatment specialists. The strategic challenge is to defend the behavioral franchise while scaling the clinical offering quickly enough to remain relevant in a market being reshaped by GLP-1 adoption and changing consumer expectations. WW’s response has been to position itself as a science-backed, personalized, multi-channel weight-health company rather than a single-product diet brand.
Geographically, WW has a global footprint, although the United States is central to its current clinical strategy and product development. The company serves consumers directly and also reaches the enterprise market through WeightWatchers for Business, which targets employers, health plans, and payers. Recent developments are particularly important. In 2025, WW undertook a major financial reorganization aimed at reducing debt and strengthening its capital structure. In 2026, the company announced leadership changes and the creation of an Office of the CEO while it searches for a permanent chief executive. Recent reported results also show continued growth in Clinical subscribers and clinical subscription revenue, underscoring that WW is still in the middle of a multi-year transition from legacy weight-loss services toward an integrated weight-health model.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
